RGV005

AXP000139.1 · Oncolytic virus

Platform
vaccinia virus (in vivo CAR-delivering)
Targets
CD19
Originator
Second Affiliated Hospital, Zhejiang University School of Medicine
Sponsor
Second Affiliated Hospital, Zhejiang University School of Medicine

Names

NameTypeSource
RGV005preferred name, codecurator, ctgov
CD19-CAR novel oncolytic vaccinia virussynonymctgov

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Replication
conditionally replicating
Modifications
oncolytic vaccinia encoding an anti-CD19 chimeric antigen receptor for in vivo CAR-T/CAR-macrophage generation
Transgenes
CAR (anti-CD19)
Route
intratumoral, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07398963Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell LymphomaRecruitingPhase 12026-022029-0748Refractory/Relapsed B-cell Lymphoma

Recent changes

No changes recorded in its trials yet.

Notes

Oncolytic vaccinia virus delivering an anti-CD19 CAR in vivo (CAR-T/CAR-macrophage), phase 1 NCT07398963 in relapsed/refractory B-cell lymphoma, intratumoral and intravenous arms, recruiting from February 2026. Distinct from CF33-CD19 (AXP000101), which instead makes tumour cells express truncated CD19: here the virus delivers the receptor to host immune cells. Strain and deletions not described.

How to cite

RGV005 (AXP000139.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000139.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.